Literature DB >> 23695220

Dynamic MR imaging of osteoid osteomas: correlation of semiquantitative and quantitative perfusion parameters with patient symptoms and treatment outcome.

Pedro A Gondim Teixeira1, Anne Chanson, Marine Beaumont, Sophie Lecocq, Matthias Louis, Béatrice Marie, François Sirveaux, Alain Blum.   

Abstract

OBJECTIVE: To evaluate the relationship between multiple MR perfusion parameters and symptoms of patients with osteoid osteomas after percutaneous laser therapy.
METHODS: MR perfusion studies of 20 patients diagnosed with an osteoid osteoma, treated with CT-guided percutaneous laser therapy, were retrospectively evaluated. Multiple perfusion parameters correlated with the treatment outcome and the presence of osteoid osteoma-related symptoms.
RESULTS: There were 16 successful treatments, 6 recurrences and a significant difference in the perfusion parameters of these groups (P < 0.0001). Patients with successful treatment demonstrated delayed progressive enhancement or no enhancement (mean time to peak = 182 s, mean delay to the arterial peak = 119.3 s). Patients with treatment failure demonstrated an early and steep enhancement (mean time to peak = 78 s and mean delay to the arterial peak = 24 s). Plasmatic volume and transfer constant values significantly changed after successful treatment (P < 0.008). MR perfusion has a sensitivity and a specificity higher than 90 % in the detection of recurrent osteoid osteomas.
CONCLUSION: The identification of an early and steep enhancement with short time to peak and a short delay between the arterial and nidus peaks on MR perfusion in the postoperative setting is highly indicative of an osteoid osteoma recurrence. Key points • Magnetic resonance perfusion is becoming widely used for several tumours. • MR perfusion measurements correlate well with osteoid osteoma-related symptoms. • MR perfusion has high diagnostic performance for osteoid osteoma recurrence. • MR perfusion can improve the diagnostic confidence of osteoid osteoma recurrence.

Entities:  

Mesh:

Year:  2013        PMID: 23695220     DOI: 10.1007/s00330-013-2867-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging.

Authors:  G Brix; W Semmler; R Port; L R Schad; G Layer; W J Lorenz
Journal:  J Comput Assist Tomogr       Date:  1991 Jul-Aug       Impact factor: 1.826

2.  Perfusion parameters analysis of the vertebral bone marrow in patients with Ph¹⁻ chronic myeloproliferative neoplasms (Ph(neg) MPN): a dynamic contrast-enhanced MRI (DCE-MRI) study.

Authors:  Nikos Courcoutsakis; Athina Spanoudaki; Thomas G Maris; Emmanuel Astrinakis; Emmanuel Spanoudakis; Constantinos Tsatalas; Panos Prassopoulos
Journal:  J Magn Reson Imaging       Date:  2011-11-08       Impact factor: 4.813

Review 3.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

4.  Dynamic computed tomography scanning of benign bone lesions: preliminary results.

Authors:  E Levine; J R Neff
Journal:  Skeletal Radiol       Date:  1983       Impact factor: 2.199

5.  Histological evaluation of drill fragments obtained during osteoid osteoma radiofrequency ablation.

Authors:  Shahram Akhlaghpoor; Alireza Aziz Ahari; Seyed Ali Ahmadi; Abbas Arjmand Shabestari; Katayoun Gohari Moghaddam; Mohammad Reza Alinaghizadeh
Journal:  Skeletal Radiol       Date:  2010-03-04       Impact factor: 2.199

6.  Combined dynamic contrast-enhancement and serial 3D-subtraction analysis in magnetic resonance imaging of osteoid osteomas.

Authors:  T von Kalle; M Langendörfer; F F Fernandez; P Winkler
Journal:  Eur Radiol       Date:  2009-05-15       Impact factor: 5.315

7.  Imaging of osteoid osteoma with dynamic gadolinium-enhanced MR imaging.

Authors:  Patrick T Liu; F Spencer Chivers; Catherine C Roberts; Christopher J Schultz; Christopher P Beauchamp
Journal:  Radiology       Date:  2003-06       Impact factor: 11.105

8.  Osteoid osteoma treated with percutaneous radiofrequency ablation: MR imaging follow-up.

Authors:  Min Hee Lee; Joong Mo Ahn; Hye Won Chung; Hyo K Lim; Jae Gon Suh; Hyon Joo Kwag; Hyun Pyo Hong; Byung Moon Kim
Journal:  Eur J Radiol       Date:  2007-08-06       Impact factor: 3.528

Review 9.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

10.  Pilot study on evaluation of any correlation between MR perfusion (Ktrans) and diffusion (apparent diffusion coefficient) parameters in brain tumors at 3 Tesla.

Authors:  Jian-Ping Chu; Henry Ka-Fung Mak; Kelvin Kai-Wing Yau; Linda Zhang; Janice Tsang; Queenie Chan; Gilberto Ka-Kit Leung
Journal:  Cancer Imaging       Date:  2012-01-23       Impact factor: 3.909

View more
  10 in total

1.  Contrast-enhanced 3T MR Perfusion of Musculoskeletal Tumours: T1 Value Heterogeneity Assessment and Evaluation of the Influence of T1 Estimation Methods on Quantitative Parameters.

Authors:  Pedro Augusto Gondim Teixeira; Christophe Leplat; Bailiang Chen; Jacques De Verbizier; Marine Beaumont; Sammy Badr; Anne Cotten; Alain Blum
Journal:  Eur Radiol       Date:  2017-06-14       Impact factor: 5.315

2.  Dynamic contrast-enhanced MR imaging in osteoid osteoma: relationships with clinical and CT characteristics.

Authors:  P Pottecher; E Sibileau; S Aho; B Hamze; C Parlier; J D Laredo; V Bousson
Journal:  Skeletal Radiol       Date:  2017-04-11       Impact factor: 2.199

3.  Treatment-related alterations of imaging findings in osteoid osteoma after percutaneous radiofrequency ablation.

Authors:  Gonca Erbaş; Halit Nahit Şendur; Hüseyin Koray Kiliç; Emetullah Cindil; Ali Yusuf Öner; Nil Tokgöz; Erhan Turgut Ilgit
Journal:  Skeletal Radiol       Date:  2019-03-06       Impact factor: 2.199

4.  Linear signal hyperintensity adjacent to the subchondral bone plate at the knee on T2-weighted fat-saturated sequences: imaging aspects and association with structural lesions.

Authors:  Pedro Augusto Gondim Teixeira; Clémence Balaj; Béatrice Marie; Sophie Lecocq; Matthias Louis; Marc Braun; Alain Blum
Journal:  Skeletal Radiol       Date:  2014-08-13       Impact factor: 2.199

5.  Serially recurrent osteoid osteoma.

Authors:  Srihari C Sampath; Srinath C Sampath; Daniel I Rosenthal
Journal:  Skeletal Radiol       Date:  2014-12-14       Impact factor: 2.199

6.  Impact of Magnetic Resonance Imaging (MRI) Findings on Management of Symptomatic Patients Following Radiofrequency Ablation (RFA) of Osteoid Osteoma (OO).

Authors:  Majid Maybody; Mohamed M Soliman; Sinchun Hwang; Adrian Gonzalez-Aguirre; Ernesto G Santos Martin; Elena Kaye; Meier Hsu; Chaya Moskowitz; John H Healey; Nicola Fabbri
Journal:  SN Compr Clin Med       Date:  2020-09-14

Review 7.  Bone marrow MR perfusion imaging and potential for tumor evaluation.

Authors:  James F Griffith; R A van der Heijden
Journal:  Skeletal Radiol       Date:  2022-10-22       Impact factor: 2.128

Review 8.  Osteoid osteoma: the great mimicker.

Authors:  Bruno C Carneiro; Isabela A N Da Cruz; Alípio G Ormond Filho; Igor P Silva; Júlio B Guimarães; Flávio D Silva; Marcelo A C Nico; Xavier M G R G Stump
Journal:  Insights Imaging       Date:  2021-03-08

9.  Correlation of 3-T MRI and CT findings with patient symptoms and treatment outcome in radiofrequency ablation of osteoid osteoma.

Authors:  Mehmet Ali Kaptan; Berat Acu; Çiğdem Öztunalı; Cüneyt Çalışır; Ulukan İnan; Muzaffer Bilgin
Journal:  Acta Orthop Traumatol Turc       Date:  2019-05-16       Impact factor: 1.511

Review 10.  Osteoid osteoma of the hip: imaging features.

Authors:  Jacques Malghem; Frederic Lecouvet; Thomas Kirchgesner; Souad Acid; Bruno Vande Berg
Journal:  Skeletal Radiol       Date:  2020-06-19       Impact factor: 2.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.